论文部分内容阅读
目的:对美罗培南治疗新生儿重症细菌感染进行疗效和安全性的研究和分析。方法:从2011年1月～2012年12月在该院接受治疗的重症细菌感染的新生儿患者中选取114例作为研究对象,采用随机数据表法将患者分为实验组和对照组,实验组给予患者美罗培南治疗,对照组给予患者头孢他啶治疗,根据《抗菌药物临床研究指导原则》为标准进行疗效比较,并对细菌敏感性和不良反应做出评价。结果:实验组对细菌的敏感性达到了100%,有效率达到了82.46%,实验组患者的治疗结果明显优于对照组,差异有统计学意义(P<0.05),不良反应两组比较差异无统计学意义(P>0.05)。结论:美罗培南在重症新生儿感染治疗中疗效确切,但存在继发真菌感染的风险,长期使用时需在早期加以抗真菌药物辅助治疗。
Objective: To study and analyze the efficacy and safety of Meropenem in the treatment of severe neonatal bacterial infections. Methods: From January 2011 to December 2012 in the hospital for treatment of severe bacterial infections in 114 newborns were selected as the research object, the use of random data table method the patients were divided into experimental group and control group, the experimental group The patients were given Meropenem treatment and the control group were treated with ceftazidime. According to the “Guiding Principles for Clinical Research of Antibacterial Drugs”, the curative effect was compared with that of the standard and the bacterial sensitivity and adverse reactions were evaluated. Results: The sensitivity of the experimental group to bacteria was 100% and the effective rate reached 82.46%. The experimental results in the experimental group were significantly better than those in the control group (P <0.05), and the difference was statistically significant No statistical significance (P> 0.05). Conclusion: Meropenem is effective in the treatment of severe neonatal infections, but there is a risk of secondary fungal infection. Anti-fungal drug adjuvant therapy is needed in the long term.